vs
Side-by-side financial comparison of IMAX CORP (IMAX) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.
IMAX CORP is the larger business by last-quarter revenue ($125.2M vs $75.5M, roughly 1.7× PUMA BIOTECHNOLOGY, INC.). On growth, IMAX CORP posted the faster year-over-year revenue change (35.1% vs 27.7%). IMAX CORP produced more free cash flow last quarter ($28.0M vs $14.4M). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 25.8%).
IMAX Corporation is a Canadian production theatre company which designs and manufactures IMAX cameras and projection systems as well as performing film development, production, post-production and distribution to IMAX-affiliated theatres worldwide. Founded in Montreal in 1967, it has headquarters in the Toronto area, and operations in New York City and Los Angeles.
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
IMAX vs PBYI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $125.2M | $75.5M |
| Net Profit | $637.0K | — |
| Gross Margin | 57.6% | 69.3% |
| Operating Margin | 19.3% | 22.7% |
| Net Margin | 0.5% | — |
| Revenue YoY | 35.1% | 27.7% |
| Net Profit YoY | -88.0% | — |
| EPS (diluted) | $0.02 | $0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $125.2M | $75.5M | ||
| Q3 25 | $106.7M | $54.5M | ||
| Q2 25 | $91.7M | $52.4M | ||
| Q1 25 | $86.7M | $46.0M | ||
| Q4 24 | $92.7M | $59.1M | ||
| Q3 24 | $91.5M | $80.5M | ||
| Q2 24 | $89.0M | $47.1M | ||
| Q1 24 | $79.1M | $43.8M |
| Q4 25 | $637.0K | — | ||
| Q3 25 | $20.7M | $8.8M | ||
| Q2 25 | $11.3M | $5.9M | ||
| Q1 25 | $2.3M | $3.0M | ||
| Q4 24 | $5.3M | — | ||
| Q3 24 | $13.9M | $20.3M | ||
| Q2 24 | $3.6M | $-4.5M | ||
| Q1 24 | $3.3M | $-4.8M |
| Q4 25 | 57.6% | 69.3% | ||
| Q3 25 | 63.1% | 77.7% | ||
| Q2 25 | 58.5% | 76.5% | ||
| Q1 25 | 61.4% | 77.1% | ||
| Q4 24 | 52.2% | 76.4% | ||
| Q3 24 | 55.8% | 63.9% | ||
| Q2 24 | 49.4% | 77.4% | ||
| Q1 24 | 59.3% | 75.5% |
| Q4 25 | 19.3% | 22.7% | ||
| Q3 25 | 27.2% | 17.6% | ||
| Q2 25 | 15.6% | 12.7% | ||
| Q1 25 | 19.3% | 8.7% | ||
| Q4 24 | 10.3% | 22.6% | ||
| Q3 24 | 21.2% | 27.4% | ||
| Q2 24 | 3.2% | -4.6% | ||
| Q1 24 | 15.3% | -5.3% |
| Q4 25 | 0.5% | — | ||
| Q3 25 | 19.4% | 16.2% | ||
| Q2 25 | 12.3% | 11.2% | ||
| Q1 25 | 2.7% | 6.5% | ||
| Q4 24 | 5.7% | — | ||
| Q3 24 | 15.2% | 25.2% | ||
| Q2 24 | 4.0% | -9.6% | ||
| Q1 24 | 4.1% | -11.0% |
| Q4 25 | $0.02 | $0.26 | ||
| Q3 25 | $0.37 | $0.17 | ||
| Q2 25 | $0.20 | $0.12 | ||
| Q1 25 | $0.04 | $0.06 | ||
| Q4 24 | $0.09 | $0.40 | ||
| Q3 24 | $0.26 | $0.41 | ||
| Q2 24 | $0.07 | $-0.09 | ||
| Q1 24 | $0.06 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $151.2M | $97.5M |
| Total DebtLower is stronger | — | $22.7M |
| Stockholders' EquityBook value | $337.9M | $130.3M |
| Total Assets | $894.0M | $216.3M |
| Debt / EquityLower = less leverage | — | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $151.2M | $97.5M | ||
| Q3 25 | $143.1M | $94.4M | ||
| Q2 25 | $109.3M | $96.0M | ||
| Q1 25 | $97.1M | $93.2M | ||
| Q4 24 | $100.6M | $101.0M | ||
| Q3 24 | $104.5M | $96.7M | ||
| Q2 24 | $91.6M | $96.8M | ||
| Q1 24 | $81.0M | $107.2M |
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
| Q4 25 | $337.9M | $130.3M | ||
| Q3 25 | $349.5M | $115.3M | ||
| Q2 25 | $320.4M | $104.7M | ||
| Q1 25 | $299.5M | $97.1M | ||
| Q4 24 | $299.5M | $92.1M | ||
| Q3 24 | $289.4M | $71.1M | ||
| Q2 24 | $267.2M | $48.5M | ||
| Q1 24 | $258.8M | $51.0M |
| Q4 25 | $894.0M | $216.3M | ||
| Q3 25 | $889.6M | $202.9M | ||
| Q2 25 | $868.6M | $194.9M | ||
| Q1 25 | $848.3M | $196.2M | ||
| Q4 24 | $830.4M | $213.3M | ||
| Q3 24 | $847.6M | $220.7M | ||
| Q2 24 | $827.4M | $205.0M | ||
| Q1 24 | $824.1M | $214.1M |
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $29.4M | $14.4M |
| Free Cash FlowOCF − Capex | $28.0M | $14.4M |
| FCF MarginFCF / Revenue | 22.3% | 19.1% |
| Capex IntensityCapex / Revenue | 1.1% | 0.0% |
| Cash ConversionOCF / Net Profit | 46.11× | — |
| TTM Free Cash FlowTrailing 4 quarters | $118.9M | $41.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $29.4M | $14.4M | ||
| Q3 25 | $67.5M | $9.7M | ||
| Q2 25 | $23.2M | $14.1M | ||
| Q1 25 | $7.0M | $3.6M | ||
| Q4 24 | $11.5M | $15.6M | ||
| Q3 24 | $35.3M | $11.0M | ||
| Q2 24 | $35.0M | $1.0M | ||
| Q1 24 | $-11.0M | $11.2M |
| Q4 25 | $28.0M | $14.4M | ||
| Q3 25 | $64.8M | $9.7M | ||
| Q2 25 | $20.9M | $14.1M | ||
| Q1 25 | $5.3M | $3.6M | ||
| Q4 24 | $6.9M | $15.6M | ||
| Q3 24 | $34.2M | $11.0M | ||
| Q2 24 | $33.5M | $1.0M | ||
| Q1 24 | $-12.1M | — |
| Q4 25 | 22.3% | 19.1% | ||
| Q3 25 | 60.7% | 17.7% | ||
| Q2 25 | 22.8% | 26.8% | ||
| Q1 25 | 6.1% | 7.7% | ||
| Q4 24 | 7.4% | 26.4% | ||
| Q3 24 | 37.3% | 13.7% | ||
| Q2 24 | 37.6% | 2.1% | ||
| Q1 24 | -15.3% | — |
| Q4 25 | 1.1% | 0.0% | ||
| Q3 25 | 2.6% | 0.0% | ||
| Q2 25 | 2.6% | 0.0% | ||
| Q1 25 | 1.9% | 0.1% | ||
| Q4 24 | 5.0% | 0.0% | ||
| Q3 24 | 1.2% | 0.0% | ||
| Q2 24 | 1.8% | 0.0% | ||
| Q1 24 | 1.4% | 0.0% |
| Q4 25 | 46.11× | — | ||
| Q3 25 | 3.27× | 1.10× | ||
| Q2 25 | 2.06× | 2.41× | ||
| Q1 25 | 2.99× | 1.21× | ||
| Q4 24 | 2.16× | — | ||
| Q3 24 | 2.54× | 0.54× | ||
| Q2 24 | 9.78× | — | ||
| Q1 24 | -3.35× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IMAX
| Technology Sales | $46.6M | 37% |
| Image Enhancement And Maintenance Services | $38.1M | 30% |
| Joint Revenue Sharing Arrangement | $20.4M | 16% |
| Maintenance | $16.3M | 13% |
| Finance Income | $2.8M | 2% |
| Other Content Solutions | $1.6M | 1% |
PBYI
Segment breakdown not available.
